Related Experiment Video

Updated: Jul 16, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

Use of high-dose liposomal amphotericin B: efficacy and tolerance

Jorge Garbino1, Angeline Adam

  • 1Division of Infectious Diseases, University Hospitals of Geneva, Geneva, Switzerland. jorge.garbino@hcuge.ch

Acta Bio-Medica : Atenei Parmensis
|March 21, 2007
PubMed

Insights

Liposomal amphotericin B (L-AmB) is a safer first-line treatment for fungal infections than older drugs. Higher doses of L-AmB show promise as a new option for difficult-to-treat cases.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Fungal infections are rising, necessitating effective treatments.
  • Amphotericin B deoxycholate (AmBd) was standard but caused severe kidney damage.
  • Liposomal amphotericin B (L-AmB) offers reduced nephrotoxicity with maintained efficacy.

Observation:

  • Published data indicate higher L-AmB doses are used when standard doses fail.
  • Animal models and early clinical data support L-AmB's use in invasive fungal infections.

Findings:

  • Liposomal amphotericin B (L-AmB) is now the preferred initial therapy for fungal infections.
  • Higher dosages of L-AmB are emerging as a viable strategy for treatment-resistant invasive fungal infections.

Implications:

  • L-AmB represents a significant advancement in managing invasive fungal infections.
  • Exploring higher L-AmB doses could expand treatment options and improve patient outcomes for refractory cases.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...